Dr. Daud reviews ASCO 2016 immunology updates

Forums General Melanoma Community Dr. Daud reviews ASCO 2016 immunology updates

  • Post
Viewing 5 reply threads
  • Replies
      Polymath
      Participant

        Thanks Celeste for this posting.  I was drawn to the Masterkey 265 study of T-Vec combined with PD-1.  I'm on the Nivo long-term now, and my specialist has suggested concurrent T-Vec.  Wow, the numbers look really promising.  I am surprised T-Vec is not discussed more on this board, especially since it's an FDA approved treatment.  I now anxiously await results of my tumor biopsy to at least know if I qualify.  Getting the treatment, because of where I live is another matter altogether though.

        Gary

        Polymath
        Participant

          Thanks Celeste for this posting.  I was drawn to the Masterkey 265 study of T-Vec combined with PD-1.  I'm on the Nivo long-term now, and my specialist has suggested concurrent T-Vec.  Wow, the numbers look really promising.  I am surprised T-Vec is not discussed more on this board, especially since it's an FDA approved treatment.  I now anxiously await results of my tumor biopsy to at least know if I qualify.  Getting the treatment, because of where I live is another matter altogether though.

          Gary

          Polymath
          Participant

            Thanks Celeste for this posting.  I was drawn to the Masterkey 265 study of T-Vec combined with PD-1.  I'm on the Nivo long-term now, and my specialist has suggested concurrent T-Vec.  Wow, the numbers look really promising.  I am surprised T-Vec is not discussed more on this board, especially since it's an FDA approved treatment.  I now anxiously await results of my tumor biopsy to at least know if I qualify.  Getting the treatment, because of where I live is another matter altogether though.

            Gary

              Bubbles
              Participant

                Hey Gary, 

                Yes!!  I have long been a fan of intralesionals (T-VEC and PV10).  Especially when they are combined with immunotherapy.  Hopefully, they will continue to do as well as this study looks!!!  Hang in there!  C

                Bubbles
                Participant

                  Hey Gary, 

                  Yes!!  I have long been a fan of intralesionals (T-VEC and PV10).  Especially when they are combined with immunotherapy.  Hopefully, they will continue to do as well as this study looks!!!  Hang in there!  C

                  Bubbles
                  Participant

                    Hey Gary, 

                    Yes!!  I have long been a fan of intralesionals (T-VEC and PV10).  Especially when they are combined with immunotherapy.  Hopefully, they will continue to do as well as this study looks!!!  Hang in there!  C

                  Mat
                  Participant

                    Thanks Celeste.  I had not seen this stat before for ipi/nivo:

                    • BRAF mutant (BRAF positive) patients had a 67% ORR to the combo.  (NOTE:  Previously BRAF status had not been a proven factor in response rate.)
                    Mat
                    Participant

                      Thanks Celeste.  I had not seen this stat before for ipi/nivo:

                      • BRAF mutant (BRAF positive) patients had a 67% ORR to the combo.  (NOTE:  Previously BRAF status had not been a proven factor in response rate.)
                      Mat
                      Participant

                        Thanks Celeste.  I had not seen this stat before for ipi/nivo:

                        • BRAF mutant (BRAF positive) patients had a 67% ORR to the combo.  (NOTE:  Previously BRAF status had not been a proven factor in response rate.)
                          Bubbles
                          Participant

                            I know, Mat.  At one point years ago, there was some data saying that BRAF status DID affect response rates to immunotherapy.  Then the pendulum shifted as data pointed to no affect on outcomes.  Now this is out.  So….not quite sure what the end result will be…  Hope they'll figure out how to get good results, quickly…for everyone!!!  C

                            Bubbles
                            Participant

                              I know, Mat.  At one point years ago, there was some data saying that BRAF status DID affect response rates to immunotherapy.  Then the pendulum shifted as data pointed to no affect on outcomes.  Now this is out.  So….not quite sure what the end result will be…  Hope they'll figure out how to get good results, quickly…for everyone!!!  C

                              Bubbles
                              Participant

                                I know, Mat.  At one point years ago, there was some data saying that BRAF status DID affect response rates to immunotherapy.  Then the pendulum shifted as data pointed to no affect on outcomes.  Now this is out.  So….not quite sure what the end result will be…  Hope they'll figure out how to get good results, quickly…for everyone!!!  C

                          Viewing 5 reply threads
                          • You must be logged in to reply to this topic.
                          About the MRF Patient Forum

                          The MRF Patient Forum is the oldest and largest online community of people affected by melanoma. It is designed to provide peer support and information to caregivers, patients, family and friends. There is no better place to discuss different parts of your journey with this cancer and find the friends and support resources to make that journey more bearable.

                          The information on the forum is open and accessible to everyone. To add a new topic or to post a reply, you must be a registered user. Please note that you will be able to post both topics and replies anonymously even though you are logged in. All posts must abide by MRF posting policies.

                          Popular Topics